Cerus(CERS) - 2023 Q2 - Quarterly Report
Cerus(CERS)2023-08-02 16:00• comply with requirements established by the FDA, including post-marketing requirements and label restrictions; and • comply with other U.S. healthcare regulatory requirements. 36 We are exposed to risks associated with the highly concentrated market for the INTERCEPT Blood System. 37 Our research and development activities involve the controlled use of hazardous materials, including certain hazardous chemicals, radioactive materials and infectious pathogens, such as HIV and hepatitis viruses. Although we ...